Potential implications of the choice among three alternative treatment targets for apolipoprotein B100 in the management of patients with type 2 diabetes and chronic kidney disease. (January 2014)

• Record Type: Journal Article
• Authors: Boronat, Mauro; García-Cantón, César; López-Ríos, Laura; Quevedo, Virginia; Lorenzo, Dionisio L; Batista, Fátima; Riaño, Marta; Nóvoa, Francisco J
• Is Part Of: Diabetes & vascular disease research. Volume 11:Number 1(2014:Jan.)
• Page Start: 53
• Page End: 59
• Publication Date: 2014-01
• Subjects: Apolipoprotein B100 -- low-density lipoprotein–cholesterol -- non-high-density lipoprotein–cholesterol -- cardiovascular risk -- lipid goals -- type 2 diabetes; Diabetic angiopathies -- Periodicals; 616.462005
• DOI: 10.1177/1479164113511834
• Languages: English
• ISSNs: 1479-1641

Abstract

This study analyses discordance rates between attainment of therapeutic goals for apolipoprotein B100 (apoB) and both low-density lipoprotein–cholesterol (LDL-C) and non-high-density lipoprotein–cholesterol (non-HDL-C) in a sample of 152 patients with type 2 diabetes and chronic kidney disease from Gran Canaria (Spain), using treatment targets recommended by the American Diabetes Association/American College of Cardiology (ADA/ACC), the European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) and by a Spanish population-based study. Among subjects with LDL-C levels at therapeutic goal, apoB was above target in 16.3% (ADA/ACC), 6.5% (ESC/EAS) and 39.1% (population-based criteria), and among subjects with non-HDL-C levels at therapeutic goal, apoB was above target in 10.5% (ADA/ACC), 1.2% (ESC/EAS) and 29.6% (population-based criteria). These findings show that clinical management would be very differently altered depending on the criteria used to set treatment targets for apoB. Cut-off points derived from population data identify a greater number of subjects suitable for a more intensive lipid-lowering therapy.